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Prion diseases are neurodegenerative disorders characterized by the aggregation of abnormally folded prion
protein (PrPSc). In this study, we focused on the mechanism of clearance of PrPSc, which remains unclear.
p62 is a cytosolic protein known to mediate both the formation and degradation of aggregates of abnormal
proteins. The levels of p62 protein increased in prion-infected brains and persistently infected cell cultures.
Upon proteasome inhibition, p62 co-localized with PrPSc, forming a large aggregate in the perinuclear
region, hereafter referred to as PrPSc-aggresome. These aggregates were surrounded with autophagosome
marker LC3 and lysosomes in prion-infected cells. Moreover, transient expression of the phosphomimic
form of p62, which has enhanced ubiquitin-binding activity, reduced the amount of PrPSc in prion-infected
cells, indicating that the activation of p62 could accelerate the clearance of PrPSc. Our findings would thus
suggest that p62 could be a target for the therapeutic control of prion diseases.
P
rion diseases are fatal neurodegenerative disorders associated with the conformational conversion of nor-
mal cellular prion protein (PrPC) to b-sheet-rich pathogenic prion protein (PrPSc)1. The histopathological
hallmarks of prion diseases are spongiform changes, marked neuronal loss and gliosis. In addition, large
amyloids composed of PrPSc can be observed in most affected brains2,3. However, the role of these aggregates in the
pathogenesis remains to be elucidated. Although the formation of neuronal inclusion bodies might be a protective
reaction of cells to reduce the levels of toxic forms of abnormal proteins4, it was reported that b-sheet-rich PrP
inhibits the catalytic activity of proteasomes5, leading to a disruption of protein homeostasis. As the ubiquitin-
proteasome system (UPS) is essential in the degradation of abnormal proteins, its impairment has been impli-
cated in the ‘‘conformational’’ disorders such as Huntington’s disease, Parkinson’s disease and Alzheimer’s
disease6, in which misfolded proteins are known to make aggregates. As the aggregates contain polyubiquitinated
proteins and also proteasomes, their build-up promotes a vicious cycle in which the UPS becomes still further
hampered7. When the UPS is disrupted, ubiquitinated proteins are transported to the perinuclear region via a
dynein-dependent retrograde transport system, where they form large complexes termed aggresomes8–10. p62,
which was originally identified as adapter proteins involved in multiple cell-signaling pathways, has recently been
reported to function in the formation of aggresomes. It has also been shown that p62 binds to ubiquitin and
interacts with an autophagosomal membrane protein, microtubule-associated protein 1 light chain 3 (LC3-
II)11–14. Thus, aggregated proteins sequestered by p62 are degraded through the autophagolysosomal pathway15,16.
Interestingly, p62 has also been found in neuronal inclusion bodies with ubiquitinated protein aggregates in
Alzheimer’s disease, Pick’s disease, dementia with Lewy bodies, Parkinson’s disease, frontotemporal lobar degen-
eration, and amyotrophic lateral sclerosis (ALS)17–22. It has been reported that PrPSc degradation is accelerated by
activation of autophagy23–25, however the mechanism of clearance of PrPSc aggregates has not been fully eluci-
dated. In this study, we investigated the role of p62 in prion-infected cell culture models and found that p62 was
co-localized with PrPSc-aggresomes, and that the activation of p62 was able to reduce the accumulation of PrPSc.
Results
Up-regulation of p62 was observed following prion infection. To investigate the expression levels of p62
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examined the levels of p62 protein in the brains of terminally sick
mice by immunoblotting. Significantly up-regulated p62 was
observed in the brains of 22L-inoculated mice, compared with that
of the control mice (Fig. 1a). Up-regulated LC3-II was also observed,
suggesting the involvement of autophagic degradation.
We next intraperitoneally inoculated 263 K prions into Syrian
hamsters and examined the levels of p62 protein in the brains of
terminally sick hamsters by immunoblotting. The levels of p62 also
increased in the brains of 263K-inoculated hamsters, compared with
those of the control hamsters (Fig. 1b). The presence of PrPSc was
identified in all infected brains.
For further experiments, we used ScN2a58 cells, persistently 22L-
infected N2a58 cells, containing high amounts of PrPSc. Immuno-
blotting revealed that the levels of p62 protein also increased in
ScN2a58 cells compared with uninfected N2a58 cells (Fig. 2a).
Moreover, the levels of p62 mRNA also significantly increased in
ScN2a58 cells (Fig. 2b).
As microglia are known to play a major role in initiating the
pathological changes in prion disease, we investigated the effects of
prion infection on p62 using a microglial cell line (MG20). We added
0.1% brain homogenates from 22L-infected mice (22 L BH) or nor-
mal mice (nBH) to MG20 cells. After serial passages, the presence of
PrPSc and up-regulation of p62 were identified in the 22L-infected
cells from passage 3 (Fig. 2c), indicating that the phenomenon was
not neuron-specific. Taken together, these data showed that up-regu-
lation of p62 subsequently occurs in vivo and in vitro due to prion
infection.
p62 co-localizes with PrPSc in prion-infected cells. It has been
reported that PrPC is retrogradely transported from the endop-
lasmic reticulum (ER) and accumulates in the cytosol as protease-
resistant and detergent-insoluble PrP upon proteasome inhibition26,
and that aggregates may contain ubiquitinated proteins27. Another
reports suggest that some of the PrP aggregates contain uncleaved
signal peptides after proteasome inhibition, indicating the existence
of ERAD-independent mechanism in which PrP fails to translocate
into the ER lumen28–30. To determine whether such PrP aggregates
are recognized by p62, we investigated the subcellular localization of
total PrP and p62 in N2a58 and ScN2a58 cells by immuno-
fluorescence staining. Under normal conditions, immunofluore-
scence for total PrP was greater in ScN2a58 cells than in N2a58
cells [Fig. 3a, MG132 (-)]. In both cell types, endogenous p62 was
distributed throughout the cytoplasm [Fig. 3a, MG132 (-)],
consistent with previous observations11,14,31. When we treated
N2a58 and ScN2a58 cells with a chemical proteasome inhibitor,
MG132 (10 mM, 24 h) to see how the impairment of UPS affects
the distribution of PrP and p62, singular p62-containing inclusions
were frequently induced at the perinuclear region in both cell types
[Fig. 3a, MG132 (1)]. Interestingly, total PrP was dramatically
localized to p62 complex in ScN2a58 cells, suggesting that
misfolded PrP tends to promote the formation of large aggresomes
in prion-infected cells. To investigate whether PrPSc is sequestered in
the p62 complex, we visualized PrPSc by immunofluorescence
staining in combination with prior treatment with guanidium salts,
which significantly increases the PrPSc signal32. After treatment with
guanidine thiocyanate, PrPSc was detected in ScN2a58 cells, but not
in N2a58 cells, and partially co-localized with endogenous p62
(Fig. 3b). Upon proteasome inhibition, a large PrP aggregate
formed in the perinuclear region, hereafter referred to as ‘‘PrPSc-
aggresome’’, and importantly, p62 relocalized to PrPSc-aggresome.
(Fig. 3b).
We next investigated whether the knockdown of p62 affects the
formation of PrPSc-aggresome. We treated p62-specific siRNA or








































































































Figure 1 | Up-regulation of p62 in prion-infected brains. (a) The levels of p62 protein in the brains of control (Cont.) or 22 L inoculated ddY mice
(n 5 3, per group). The amount of p62, LC3 and PK-resistant PrP (M20) was analyzed by immunoblotting. b-actin was used as a loading control.
Statistical significance was evaluated using Student’s t-test. (b) The levels of p62 protein in the brains of control (Cont.) or 263 K inoculated Syrian
hamsters. The amount of p62, LC3 and PK-resistant PrP (3F4) was analyzed by immunoblotting. b-actin was used as a loading control. Statistical
significance was evaluated using Student’s t-test.
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treatment (10 mM, 24 h). As expected, in control siRNA-treated
cells, the PrPSc-aggresomes formed after proteasome inhibition
(Fig. 4). In contrast, in p62 siRNA-treated cells, in which p62 fluor-
escence was successfully decreased, PrPSc-aggresomes did not form,
suggesting the presence of p62 to be crucial for PrPSc-aggresome
formation.
p62 relocalized to PrPSc-aggresomes through ubiquitin-binding.
p62 is known to interact with ubiquitinated proteins through its C-
terminus ubiquitin-associated domain (UBA)33. To investigate
whether or not the co-localization of p62 and PrPSc was dependent
on the domain, we introduced expression vectors of HA-tagged p62
or UBA domain-deleted p62 (p62DUBA, missing amino acids 388–
442) into ScN2a58 cells and visualized p62 and PrPSc. As expected,
HA-tagged p62 relocalized to PrPSc-aggresomes upon proteasome
inhibition (Fig. 5). In contrast, HA-tagged p62DUBA did not
relocalize to PrPSc-aggresomes, suggesting that the UBA domain
plays a critical role in p62 recruitment to PrPSc-aggresomes. The
levels of p62 protein increased by MG132 (10 mM, 24 h),
and ubiquitinated proteins with high-molecular-weight (HMW,
,250 kDa), which are likely to derive from the aggresomes, were
evident in ScN2a58 cells (Fig. S1), suggesting that PrPSc-aggresomes
contain large ubiquitinated proteins.
PrP is co-immunoprecipitated with p62. We next performed co-
immunoprecipitation experiments using ScN2a58 cell lysates.
Endogenous p62 was co-immunoprecipitated with anti-PrP anti-
body (SAF32) both without (Fig. S2, top left) and with proteasome
inhibition (Fig. S2, top right). The presence of PrP in SAF32
immunoprecipitates was also identified in both lysates (Fig. S2,
bottom).
p62-positive aggresomes in prion-infected cells are surrounded by
lysosomes. We next investigated the localization of such aggresomes
and lysosomes in ScN2a58 cells, and we showed that p62-positive
aggresomes were surrounded by lysosomes (Fig. 6a). Similar result
was obtained in PrP-positive aggresomes (Fig. 6b). We also observed
that LC3 was concentrated in the aggresomes (Fig. 6c). These results
suggest that such aggresomes are potentially degraded in lysosomes.
p62 is involved in the degradation of PrPSc. To investigate whether
overexpression of p62 affects the degradation of PrPSc, a HA-tagged
p62 was introduced into N2a58 cells or ScN2a58 cells, and the
amount of PrPSc was analyzed. Transient expression of p62 had no
effect on the amount the amount of PK-resistant PrP (Fig. 7a). It has
been shown that the activity of p62 appears to be controlled by
phosphorylation at serine 403 (S403) of the human p62 UBA
domain due to enhancement of its affinity to polyubiquitin,
promoting efficient autophagic degradation of ubiquitinated
proteins34. To investigate whether phosphorylation of the UBA
domain affects the clearance of PrPSc, a HA-tagged phosphomimic
mutant, with the substitution of mouse p62 serine 405 for glutamate
(corresponding to S403 in human p62) (Fig. 7b), was introduced into
ScN2a58 cells and the amount of PrPSc was analyzed. Transient
expression of phosphomimic p62-HA reduced the amount of PrPSc
in ScN2a58 cells (Fig. 7c). To confirm whether the mutation
enhanced the affinity between p62 and ubiquitinated proteins, the
lysates from transfected cells were immunoprecipitated with anti-
HA antibody, and ubiquitinated proteins in the immunoprecipitates
were detected by immunoblotting. As expected, the amount of
ubiquitinated proteins in phosphomimic p62 transfected cells was
greater than those in mock or wild-type transfected cells (Fig. 7d). In
addition, after the blocking of lysosomal degradation by ammonium
chloride, phosphomimic p62 was largely localized in lysosomes (Fig.
S3). Taken together, these results suggest that phosphomimic p62
accelerated the clearance of PrPSc in lysosomes.
Discussion
Our study revealed the following. (1) p62 increased in association
with prion-infection in cell cultures and brains (Fig. 1 and 2); (2)
Large PrPSc aggregates encircled by p62 form when the UPS is dis-
rupted (Fig. 3b); (3) The interaction of p62 with polyubiquitin is
crucial to the formation of PrPSc-aggresomes (Fig. 5); and (4) the
constitutively active form of p62 could reduce the amount of PrPSc
in infected cells (Fig. 7c). These findings suggest that p62-mediated
aggresome-formation could be important in the host-defense res-
ponse against prion infection.
Contrary to our data, Xu et al35 previously reported that the levels
of p62 protein and ubiquitinated proteins were decreased in the
brains of 263K-infected hamsters. This discrepancy is unknown,





























































Figure 2 | Up-regulation of p62 in prion-infected cell cultures. (a) The
levels of p62 protein in N2a58 and ScN2a58 cells. The amount of p62 and
PK-resistant PrP (M20) was analyzed by immunoblotting. b-actin was
used as a loading control. (b) The levels of p62 mRNA in N2a58 and
ScN2a58 cells were analyzed by Real time PCR. Asterisks indicate
statistically significant differences (***, P , 0.001; a two-tailed Student’s
t-test; n 5 8). (c) The levels of p62 protein in de novo infection of 22 L
prion strain in MG20 cells. After the treatment of 0.1% 22 L BH or nBH to
MG20 cells, the amount of p62 and PK-resistant PrP (M20) was analyzed
by immunoblotting. b-actin was used as a loading control.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 4504 | DOI: 10.1038/srep04504 3
Several different reports have described that the levels of p62 protein
are known to be increased when proteasome function is inhib-
ited18,20,36. In prion-infected animal brains, proteasome activities
are known to be reduced, and it has been clearly evidenced that
PrPSc binds to the 20S core particle of proteasomes in vitro37 and
inhibit proteasome activity in neurons5. Actually, it has recently been
reported that transcription factor NF-E2-related factor 2 (Nrf2),
which enhances the expression of p6238, was activated when the
UPS is impaired39. Furthermore, as p62 interacts with Keap1, which
regulates the turnover of Nrf2, the up-regulated p62 may competi-
tively inhibit the Nrf2–Keap1 interaction, resulting in stabilization of
Nrf2 followed by transcriptional activation of p6240. This positive
feedback loop may contribute to the up-regulation of p62 demon-
strated in this study in the large PrPSc-aggresomes forming in
infected cells when proteasomes were inhibited by MG132. These
findings suggest that direct inhibition of the UPS by PrPSc prompts
the up-regulation of p62 as a compensatory mechanism of the UPS in
prion diseases.
It is well known that p62 can bind to polyubiquitinated proteins
and play a role in the degradation of misfolded proteins such as the
polyglutamine-expanded huntingtin34. Relatively large PrPSc-aggre-
somes encircled by p62 were observed in infected cells when the UPS
was disrupted, suggesting that p62 mediates PrPSc-aggresome forma-
tion (Fig. 3b). Because it is not clear whether PrPSc itself is ubiquiti-
nated or not, we cannot exclude the possibility that p62 binds































































Figure 3 | Co-localization of p62 and PrP after proteasome inhibition. (a) Total PrP (SAF32: green) and p62 (red) were visualized in N2a58 and
ScN2a58 cells with (1) or without (2) MG132 (10 mM, 24 h). Bars: 20 mm. (b) After the treatment of guanidine thiocyanate, PrPSc (SAF61: green) and
















Figure 4 | Knockdown of p62 disrupts the formation of PrPSc-aggresome.
ScN2a58 cells were treated with p62-specific siRNA or control siRNA
(50 nM, 48 h), following MG132 treatment (10 mM, 24 h). After the
treatment of guanidine thiocyanate, PrPSc (SAF61: green) and p62 (red)





















Figure 5 | UBA of p62 is required for the formation of PrPSc-aggresome.
(a) Scheme of HA-tagged p62 or UBA domain-deleted p62 (p62DUBA,
missing amino acids 388–442). (b) HA-tagged p62 or p62DUBA
expression vectors were transiently expressed in ScN2a58 cells for 48 h,
following with MG132 (10 mM, 24 h). After the treatment of guanidine
thiocyanate, PrPSc (SAF61: green) and HA (red) were visualized.
www.nature.com/scientificreports
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complexes is dependent upon the presence of other ubiquitinated
proteins in the PrPSc-aggresomes because these are often observed in
PrP plaques in CJD brains41,42. Based on the fact that the phospho-
mimic p62, which has enhanced ubiquitin-binding activity, pro-
moted the clearance of PrPSc (Fig. 7c), we came to the conclusion
that activation of p62 is important for the efficient clearance of PrPSc.
It has been reported that p62 and its association with ubiquitin is
involved in the clearance of neuronal inclusion bodies such as a-
synuclein43, polyglutamine-expanded huntingtin34 and androgen
receptor44, through the autophagy-lysosome pathway. In addition,
it has very recently reported overexpression of p62 promotes the
degradation of some mutant PrPs such as PrP-PG14, a PrP mutant
with the extra nine-octapeptide insertion associated with genetic
CJD and PrP-CYTO, a PrP mutant without signal peptide and GPI
anchor45. In our study, we have provided evidence that overexpres-
sion of p62 promotes the degradation of pathogenic prion protein,
although the effect is limited to phosphomimic form of p62. Taking
into account that non-phosphorylated p62 has relatively low affinity
for ubiquitin, phosphorylation of p62 is important for the efficient
degradation.
In conclusion, disruption of the UPS may be involved in prion
pathogenesis, while the enhancement of p62-activity is a possible
therapeutic target for the induction of the autophagic clearance of
pathogenic prion proteins.
Methods
Antibodies. Anti-p62/SQSTM1 (MBL, PM045), anti-b-actin (Sigma-Aldrich), anti-
HA (Invitrogen), anti-ubiquitin (Santa Cruz Biotechnology, P4D1), anti-LC3B (Cell
Signaling Technology, #2775), and anti-PrP (Santa Cruz Biotechnology, M20; SPI-
Bio, SAF61 and SAF32; SIGNET, 3F4) antibodies were purchased from the indicated
vendors. Horseradish peroxidase-conjugated anti-goat (Santa Cruz Biotechnology),
anti-mouse and anti-rabbit IgG antibodies (GE Healthcare Life Sciences) were used
for immunoblotting. Alexa FluorH 488-conjugated anti–mouse IgG and Alexa FluorH
594-conjugated anti–rabbit IgG antibodies (Invitrogen) were used for
immunofluorescence analysis.
Cell cultures. The mouse neuroblastoma Neuro 2a cells were obtained from the
American Type Culture Collection (CCL 131). N2a58 cells are mouse PrPC
overexpressing Neuro 2a cells, and ScN2a58 cells originated from N2a58 cells infected
with a mouse-adapted scrapie strain, 22 L, as previously described46,47. The cells were
cultured in Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich)
containing 10% heat-inactivated fetal bovine serum (FBS) and penicillin-
streptomycin (Invitrogen). MG20 cells (a gift from Dr. Iwamaru), isolated from
neonatal tga20 mice that overexpress mouse PrPC48, were cultured in DMEM
containing 10% heat-inactivated FBS, penicillin-streptomycin, 2-mercapto-ethanol
and insulin. All cultured cells were maintained at 37uC in 5% CO2 in the biohazard
prevention area of Nagasaki University.
Plasmids and siRNA. Mouse p62 open reading frame was amplified from N2a58
cDNA with primers of mp62-BamHI-F (59-cgcggatccgcggttatggcgtcgttcacg-39) and
mp62-XhoI-R (59-ccgctcgagtcattaagcgtaatctggaacatcgtatgggtacaatggtggagggtgctt-39).
UBA domain-deleted p62 (p62DUBA, missing amino acids 388–442) was amplified
with primers of mp62-BamHI-F and mp62DUBA-XhoI-R (59-
ccgctcgagtcattaagcgtaatctggaacatcgtatgggtaatgtgggtatagggcagcttc-39).
phosphomimic p62 was amplified with primers of mp62 (S405E)-BamHI-F (59-
tcccagatgctggagatgggcttctctgat-39) and mp62 (S405E)-XhoI-R (59-
atcagagaagcccatctccagcatctggga-39). Amplified PCR fragments were inserted into the
BamHI and XhoI sites of expression plasmid pcDNA3.1 (Invitrogen) and confirmed
by sequential analysis. All plasmids were introduced by Lipofectamine LTX
(Invitrogen) in prion-infected cells and analyzed 48 h after transfection. ON-
TARGETplus small interference RNA (siRNA) against mouse p62 (J-047628-12-
0005) was purchased from Thermo Scientific as well as the control ON-TARGETplus
non-targeting siRNA (D-001810-01-05). Transfection with siRNAs was carried out
with Lipofectamine 2000 (Invitrogen) according to the manufacturer’s protocol.
Immunoblotting. Immunoblotting analysis was performed as previously
described49. Briefly, samples were lysed with cold lysis buffer (50 mM Tris-HCl pH
7.5, 150 mM NaCl, 0.5% Triton X-100, 0.5% sodium deoxycholate, 2 mM EDTA)
containing protease inhibitors (Nacalai Tesque, Inc., Kyoto, Japan) for 30 min at 4uC.
After 10 min of centrifugation at 15,000 3 g, the supernatant was collected, and the
concentration of total protein was measured using BCA Protein Assay Kit (Pierce).
For PrPSc detection, samples were digested with 40 mg/ml of proteinase K (PK; Sigma-
Aldrich) at 37uC for 30 min, boiled for 5 min with SDS loading buffer (50 mM Tris-
HCl pH 6.8, 5% glycerol, 1.6% SDS, 100 mM dithiothreitol), and subjected to
SDS-PAGE. The proteins were transferred onto an Immobilon-P Membrane
(Millipore) in transfer buffer containing 15% methanol at 300 mA for 90 min; the
membrane was blocked with 5% nonfat dry milk in TBST (10 mM Tris-HCl pH 7.8,
100 mM NaCl, 0.1% Tween 20) for 30 min at room temperature and further
incubated with primary antibodies. The immunoreactive bands were visualized using
ECL Western Blotting Detection Kit (GE Healthcare Life Sciences).
Real-time PCR. Total RNA was isolated from cells using a TRIZOLH Reagent
(Invitrogen). The first-strand cDNA was synthesized from 2 mg of total RNA with
Super Script III Reverse Transcriptase (Invitrogen). The primers were: 59-
gctgccctatacccacatct-39 and 59-cgccttcatccgagaaac-39 for p62 and 59-
aaatcgtgcgtgacatcaaa-39 and 59-aaggaaggctggaaaagagc-39 for b-actin. b-actin mRNA
was determined as a positive control. For real-time PCR, the synthesized cDNA was
reacted with Fast Start Universal SYBR Green Master (Roche Applied Science) and
measured by Light CyclerH 480 (Roche Applied Science).
Immunofluorescence analysis. Cells were fixed for 30 min at room temperature in
4% formaldehyde in PBS, permeabilized for 5 min at room temperature with 0.5%
Triton X-100 in PBS, treated with 3 M guanidine thiocyanate for 5 min, blocked for
1 h at room temperature in TBST containing 5% skim milk, and incubated overnight
at 4uC with the primary antibody in TBST containing 1% skim milk. After three
washes in PBS, cells were incubated with the appropriate Alexa FluorH-conjugated
secondary antibodies (dilution 15200) for 90 min at 37uC. For lysosomal staining,
cells were stained with LysotrackerH dye (prepared according to kit instructions) for
30 min at 37uC. All images were obtained using a confocal laser-scanning microscope
(Carl Zeiss).
Co-immunoprecipitation. ScN2a58 cells were grown to confluence in a 60 mm dish
and treated with MG132 (10 mM, 24 h), and then harvested. Cells were lysed using
cold immunoprecipitation lysis buffer (150 mM NaCl, 10 mM EDTA, 10 mM
KH2PO4 pH 7.5) containing 2% Triton X-100. Cell debris was removed by
centrifugation and the lysates were pre-cleaned for 30 min with protein G-
SepharoseTM 4 Fast Flow (GE Healthcare Life Sciences). After the protein G-
Sepharose was removed by centrifugation, the supernatant was incubated at 4uC with
anti-p62 or anti-rabbit IgG antibodies for 2 h. Protein G-Sepharose was then added to
the supernatant and incubation was continued for another 1 h. The
immunoprecipitates were washed six times with washing buffer (150 mM NaCl,
10 mM Tris-HCl pH 7.4, 0.2% Tween-20), and resuspended in 2 3 loading buffer.
In vivo infection experiments. Four-weeks-old ddY mice were purchased from SLC
(Hamamatsu, Japan) and were intracerebrally inoculated with 20 mL of a 1021






Figure 6 | Aggresomes in prion-infected cells are surrounded by
lysosomes. (a) p62 (green) and lysosome (red) were visualized in ScN2a58
cells treated with MG132 (10 mM, 24 h). Bars: 20 mm. (b) Total PrP
(SAF32: green) and lysosome (red) were visualized in ScN2a58 cells treated
with MG132 (10 mM, 24 h). Bars: 20 mm. (c) Total PrP (SAF32: green) and
LC3 (red) were visualized in ScN2a58 cells treated with MG132 (10 mM,
24 h). Bars: 20 mm.
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dilution of brain homogenate prepared from mice terminally sick with 22 L strain. As
a control, age- and strain-matched mice were intracerebrally inoculated with
phosphate buffered saline. The brains of the mice were removed at the terminal stage
of disease. Animals were cared for in accordance with the Guidelines for Animal
Experimentation of Nagasaki University.
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Figure 7 | Transient expression of phosphomimic p62 reduces the amount of PrPSc. (a) Mock or HA-tagged p62 expression vectors were transfected into
N2a58 or ScN2a58 cells. The amount of PK-resistant PrP (M20) was analyzed by immunoblotting. The expression of transfected vectors was identified by
anti-HA antibody. b-actin was used as a loading control. (b) Scheme of HA-tagged phosphomimic p62 (substitution of mouse p62 serine 405 for
glutamate). (c) Mock or HA-tagged phosphomimic p62 expression vectors were transfected into ScN2a58 cells. The amount of PK-resistant PrP (M20)
was analyzed by immunoblotting. The expression of transfected vectors was identified by anti-HA antibody. b-actin was used as a loading control. The
amount of PK-resistant PrP was digitized and statistically analyzed using a two-tailed Student’s t-test (*, P , 0.01). Data are presented as mean 6 SD of
three independent experiments. (d) Mock, HA-tagged p62, or phosphomimic p62 expression vectors were transfected into ScN2a58 cells. The lysates were
then subjected to co-immunoprecipitation with anti-HA antibody, and blotted for anti-ubiquitin (top) and anti-HA (bottom) antibodies.
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